ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1852

Adenosine A2A Receptors (A2AR) Promote Scarring By Repressing Mir-29a

Ross C. Radusky1, Miguel Perez-Aso2, Andrew G. Franks Jr.3, Bruce N. Cronstein4 and Edwin SL Chan1, 1Medicine, New York University School of Medicine, New York, NY, 2Department of Translational Medicine, New York University School of Medicine, New York, NY, 3Dermatology & Medicine (Rheumatology), New York University, New York, NY, 4Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

We have previously demonstrated that the nucleoside adenosine stimulates collagen production and induces dermal fibrosis in vitro and in vivo. Recent studies have demonstrated the presence and significance of microRNAs in various disease conditions and, in fibrosing conditions, diminished levels of miR-29a are found in the skin and other organs that have undergone fibrosis. We therefore determined whether adenosine A2AR stimulation regulates the expression and levels of miR29a in skin at fibrotic sites. 

Methods:

In this investigation, human dermal fibroblasts were treated with the A2AR specific agonist (CGS21680). Changes in miR-29a, collagen1 and collagen3 expression were analyzed by real-time PCR. An in vivo model of hypertrophic scarring previously described (Perez-Aso et al. 2012) was used to analyze the impact of A2AR pharmacological blockade with the specific A2AR antagonist ZM241385 on miR-29a expression in the skin: 12mm incisional wounds were splinted to promote chronic scarring in a total of 32 C57BL/6 mice. Mice were topically treated with either the A2AR antagonist or vehicle (3% carboxymethylcellulose and 7.4% DMSO) alone as a control. Scar progression was quantified using trichrome staining for collagen deposition.

Results:

In in vitro studies A2AR stimulation with increasing concentrations of CGS21680 (0.01, 0.1 and 1μM) reduced the expression of miR-29a (table 1) and the A2AR agonist CGS21680 (1μM) stimulated an increase of both collagen1 and collagen3 (table 2). In vivo investigation yielded parallel results. Trichrome stains revealed that collagen deposition in the scar was reduced by topical application of the A2AR antagonist ZM241385 (2.5mg/ml). Changes in miR-29a expression in the scar were analyzed at the end of the investigation. Scarring decreased miR-29a expression by 46.3±4.8%; (P<0.001 vs unwounded skin, n=7) and A2AR blockade with the antagonist ZM241385 stimulated a dramatic increase of miR29a (191.7±4.8% of unwounded skin; ZM241385 vs vehicle P<0.01, n=7). 

Conclusion:

The findings of the present work indicate that A2AR activation represses miR-29a in vitro and, in a similar fashion, in vivo. These findings indicate that targeting A2AR may be a novel therapeutic target in scleroderma that mediates its action, at least in part, by diminishing miR29a, in promoting wound healing and preventing pathologic fibrosis such as that observed in hypertrophic scarring or scleroderma. 

Table 1

 

CGS21680 (µM)

 

0.01

 

0.1

 

1

 

 

 

miR-29a inhibition (%)

28.3

57.5

32.9

50.5

11.1

46

 

 

 

Table 2

 

Collagen 1 (% of control)

143.3

252.3

Collagen 3 (% of control)

282.2

218.9


Disclosure:

R. C. Radusky,
None;

M. Perez-Aso,
None;

A. G. Franks Jr.,

Stiefel Pharmaceuticals,

5;

B. N. Cronstein,

Canfite Pharma,

1,

NIH, Gilead, Takeda, AstraZeneca,

2,

NYU School of Medicine,

3,

Merck-SeronoBristol-Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc., Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector,

5,

Multiple patents on adenosine receptors and bone metabolism, pharmacology,

9;

E. S. Chan,

Patent on the use of adenosine A2A antagonists for the treatment of fibrosis.,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptors-a2ar-promote-scarring-by-repressing-mir-29a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology